stockrow
Friday 6 November 2026
Export TRVI’s income statement to Excel — free account
Trevi Therapeutics, Inc.
TRVI Healthcare Biotechnology
- EPS
- −22.2%
- Free cash flow
- −73.8%
Quarter to June 2026, against a year earlier
14.22
1.41
+11.01%
Follow TRVI
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
21.93 | 19.66 | 24.75 | 37.28 |
Net Debt/EBITDA |
14.05 | 18.48 | 11.55 | 15.57 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 0.92 | 1.27 | 0.98 | |
Capex/Depreciation |
(0.32) | 0.00 | (3.00) | (3.65) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.08) | (0.06) | (0.12) | (0.11) | |
Cash per Share |
1.34 | 1.40 | 1.18 | 2.04 | |
Shareholders Equity per Share |
1.31 | 1.36 | 1.18 | 2.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.31 | 1.36 | 1.18 | 2.05 | |
Free Cash Flow |
(10.89) | (7.63) | (16.79) | (17.55) | |
Working Capital |
189.26 | 181.91 | 169.01 | 316.97 | |
Capital Expenditures |
(0.01) | 0.00 | (0.10) | (0.12) | |
Net Current Asset Value |
188.73 | 181.46 | 168.64 | 316.69 | |
| Other line items | |||||
Quick Ratio |
21.56 | 19.31 | 24.14 | 36.50 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.06) | (0.11) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.16 | 3.66 | 1.82 | 3.04 | |
Average Assets |
134.13 | 152.17 | 143.31 | 269.43 | |
Average Common Equity |
124.38 | 141.44 | 135.79 | 260.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026